newsfilter
← Earnings
Earnings Releases·

Celldex Therapeutics — Third Quarter 2026 Earnings Summary

Celldex Therapeutics reported third-quarter 2026 financial results showing a net loss of $75.6 million and cash reserves of $650.3 million. The company announced best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies for barzolvolimab in chronic spontaneous urticaria, with a Biologics License Application submission anticipated in 2027. Barzolvolimab is currently being evaluated in Phase 3 trials for cold urticaria and symptomatic dermographism, while enrollment is complete for a Phase 2 study in atopic dermatitis. Additionally, the company discontinued its Phase 2 prurigo nodularis study after data suggested mast cells were not the key pathogenic driver in that condition.

Company
CELLDEX THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology